Its roles Owner Operator Offtaker
Bayer AG is a German multinational life science and chemical company headquartered in Leverkusen, founded in 1863. Its core businesses span Pharmaceuticals, Consumer Health, and Crop Science, with activities ranging from discovery and development to large‑scale manufacturing of active pharmaceutical ingredients (such as acetylsalicylic acid), over‑the‑counter health products, seeds, and crop protection chemicals. The company operates a global network of research, production, and distribution sites, including regional entities such as Bayer Taiwan Co., Ltd.
For the chemical industry, Bayer is notable for its pharmaceutical and agrochemical process chemistry and legacy in materials science; its materials business was separated as Covestro in 2015. Bayer is pursuing energy transition measures in its operations, including long‑term power and heat purchase agreements to support electrification and decarbonization at manufacturing sites, such as the acetylsalicylic acid plant in La Felguera, Spain.
Also known as Bayer Group, Bayer AG Taiwan Branch, Bayer Taiwan Co., Ltd., and Bayer Taiwan.
chemXplore tracks 23 projects involving Bayer, of which 6 are active.
Besides these 6, the record holds 16 completed projects and 1 cancelled.
Closest to start-up first.
The 17 that are completed, on hold or cancelled are in the record. See all 23 in chemXplore →
Jury cleared Monsanto on design‑defect, fraud and negligence claims in a three‑plaintiff case — the first Roundup trial after the Supreme Court’s June 2026 Durnell ruling.
First Factor XIa inhibitor worldwide approved to lower recurrent ischemic stroke risk after non‑cardioembolic stroke or high‑risk TIA in adults.
Interim Phase III DASL-HiCaP results show darolutamide added to ADT and radiation significantly improves metastasis-free survival versus placebo in high‑risk patients.
Randomized Phase II will test VVD-214 plus pembrolizumab versus pembrolizumab alone as first‑line treatment for advanced MSI‑high/dMMR colorectal cancer, enrolling ~140 patients.
FDA acceptance of finerenone sNDA for adults with CKD without diabetes follows Phase III FIND‑CKD showing slower eGFR decline and reduced cardio‑kidney events versus placebo.
2.2 billion USD project in New Albany will add ~600 permanent roles and ~1,500 construction jobs; first drug substance module operational in 2031, drug product in 2034.
Ten projects won awards across six categories for initiatives linking electrification, biodiversity and rural development, from industrial decarbonisation to community energy and journalism.
Investigational iPSC-derived cell therapy for primary photoreceptor diseases receives orphan status across multiple inherited retinal disorder indications; being tested in a Phase 1/2a trial.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
